|
|
|
|
|
|
Sponsors struggle to meet enrollment numbers, particularly when it comes to rare disease studies. Delayed diagnoses, small patient pools, and complex protocols contribute to the problem. Let’s look at the landscape, the obstacles, and how to pave a new path forward.
|
|
|
|
|
The market for rare disease treatments continues to grow as pharma and biotech companies prioritize innovation in areas of high and unmet need amid advances in cell and gene therapies and precision medicine. An increase in rare disease research amplifies the need to recruit these hard-to-find patients.
|
|
|
|
|
As a child, Citeline’s Haley Quinn experienced persistent joint dislocations. She and her family went from doctor to specialist, X-ray to MRI, and surgery after surgery. Nothing worked. After multiple surgeries and thousands of dislocations later, Haley was finally diagnosed with three rare diseases. Failure to diagnose or incorrect diagnoses are one reason sponsors find it so difficult to recruit rare disease patients for clinical trials.
|
|
|
|
|
Traditional recruitment methods weren’t cutting it for this Phase II cancer study, so the sponsor turned to Citeline for a unique approach. See how Citeline PatientMatch leveraged data and artificial intelligence to help pinpoint the right patients.
|
|
|
|
|
In an effort to boost enrollments rapidly for a Sol-Gel study on Gorlin syndrome, Citeline launched a 60-day HCP Awareness campaign. Citeline’s targeted email campaign surpassed industry benchmarks and generated a substantial number of leads.
|
|
|
|
|
Before you invest in a patient recruitment solution, know what questions to ask and what features to look for. Our buyer’s guide details how a solution can amplify and optimize trial recruitment across all studies to help you hit enrollment goals faster. The guide also reveals how a solution facilitates dialogue, awareness, community, trust, and participation around clinical research.
|
|
|
|
|
